


# INFORMATION DISCLOSURE STATEMENT BY APPLICANT



Complete if Known

Application Number 09/645,590  
Filing Date August 25, 2000  
First Named Inventor Markku KOULU  
Group Art Unit ~~1045~~ 1635  
Examiner Name Unassigned

Sheet

1

2

Attorney Docket Number 2630-106

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
M		WO96	34877	A1	Human Genome Sciences, Inc.	11/07/1996	
^		WO99	32518	A1	Hormos Medical Oy Ltd.	07/01/1999	

Examiner  
Signature

Date  
Considered

11/13/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code.

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

RECEIVED

FEB 28 2002

TECH CENTER 1600/2900

FEB 27 2002

PATENT & TRADEMARK OFFICE

Application Number	09/645,590
--------------------	------------

Filing Date	August 25, 2000
-------------	-----------------

First Named Inventor	Markku KOULU
----------------------	--------------

Group Art Unit	1635
----------------	------

Examiner Name	Unassigned
---------------	------------

Sheet	2	of	2	Attorney Docket Number	2630-106
-------	---	----	---	------------------------	----------

Examiner  
Initials\*Cite  
No.<sup>1</sup>

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

 $T^2$ 

J. Kallio et al., "Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans," The FASEB Journal 15:1242-1244, May 2001.

J.M. Lundberg et al., "Co-Release of Neuropeptide Y and Catecholamines During Physical Exercise in Man," *Biochemical and Biophysical Research Communications* 133(1):30-36, November 27, 1985.

M.J. Morris et al., "Region-Specific Neuropeptide Y Overflows at Rest and During Sympathetic Activation in Humans," *Hypertension* 29:137-143, 1997, American Heart Association, Inc. (actual number of pages of this article: 25)

Examiner  
Signature

Date  
Considered

11/13/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.